Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Resectable Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Lei Gong, MD) · leigong@tmu.edu.cn · 13820389526

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

Esophageal Squamous Cell Carcinoma · Ivonescimab · Neoadjuvant

Abroad (travel likely)RecruitingPHASE1, PHASE2

Xi'an, China

Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma · Neoadjuvant Therapy

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Hanzhou, China · Hanzhou, China